新闻动态
AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024
Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy targeting LN and SLE
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4
AbelZeta Announces Publication of Abstract for ASCO 2024 Annual Meeting
…data from its C-CAR031 study has been published in an abstract available on the 2024 American Society of Clinical Oncology’s (ASCO) official website.
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AbelZeta announces acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC)
AbelZeta Announces Formation of Scientific Advisory Board to Support Inflammatory and Immunological Diseases
AbelZeta forms Scientific Advisory Board (the “SAB”) to advance its cell therapies for the treatment of inflammatory and immunological diseases.
AbelZeta to Present at the Annual J.P. Morgan Healthcare Conference
Abelzeta announced that Tony (Bizuo) Liu, Chairman and CEO, will present an update on the Company at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China
Amended worldwide collaboration and license agreement for CD20-directed chimeric antigen receptor T (CAR-T) C-CAR039 and C-CAR066 to include an option for commercialization of products in China.
AbelZeta Presents Data from Two Clinical Studies Relating to its Immuno-Oncology Drug Development at the 65th ASH Annual Meeting
AbelZeta Pharma, Inc. presented clinical data for both C-CAR039 for the treatment of patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL), and C-CAR066, for the treatment of patients with r/r large B-cell lymphoma (LBCL) who failed prior CD19 CAR-T therapy at the 65th American Society of Hematology (ASH) Annual Meeting.
AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China
ROCKVILLE, MD and SHANGHAI, China, December 7, 2023 – AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer, inflammatory and immunological diseases, today announced an agreement with AstraZeneca to co-develop C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, in hepatocellular carcinoma (HCC).
AbelZeta Announces Two Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, announced today that two abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.